Trial Profile
A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 May 2019
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 16 Apr 2019 Results of PK/PD modelling and simulation to support paediatric dosing using data from NCT01893346, NCT02475733 and NCT02497781 trials, presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy